Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 6,092 Shares of Stock

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 6,092 shares of Natera stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total value of $851,722.52. Following the sale, the chief executive officer directly owned 169,400 shares of the company's stock, valued at $23,683,814. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, July 21st, Steven Leonard Chapman sold 1,622 shares of Natera stock. The stock was sold at an average price of $139.29, for a total value of $225,928.38.
• On Tuesday, July 1st, Steven Leonard Chapman sold 5,343 shares of Natera stock. The stock was sold at an average price of $166.53, for a total value of $889,769.79.
• On Monday, June 2nd, Steven Leonard Chapman sold 6,111 shares of Natera stock. The stock was sold at an average price of $157.10, for a total value of $960,038.10.

Natera Stock Down 2.7%

Shares of NASDAQ:NTRA traded down $3.80 during trading on Thursday, reaching $137.17. 223,968 shares of the company traded hands, compared to its average volume of 1,486,227. The firm has a fifty day simple moving average of $158.12 and a 200 day simple moving average of $156.45. The firm has a market cap of $18.73 billion, a P/E ratio of -92.98 and a beta of 1.73. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. Natera's revenue for the quarter was up 36.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.56) EPS. As a group, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NTRA. UBS Group boosted their target price on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Piper Sandler boosted their price target on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday. One equities research analyst has rated the stock with a sell rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $183.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD lifted its position in Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after acquiring an additional 3,871,862 shares during the last quarter. Nuveen LLC acquired a new position in shares of Natera during the first quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Natera by 140.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company's stock valued at $177,298,000 after buying an additional 732,156 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after buying an additional 660,538 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Natera by 40.0% during the fourth quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company's stock valued at $243,604,000 after buying an additional 439,540 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.